ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

MXCT Maxcyte Inc

342.50
-2.50 (-0.72%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Maxcyte Inc LSE:MXCT London Ordinary Share COM STK USD0.01 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.50 -0.72% 342.50 335.00 350.00 345.00 342.50 345.00 24,274 16:17:54
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 44.26M -23.57M -0.2277 -18.40 433.68M
Maxcyte Inc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker MXCT. The last closing price for Maxcyte was 345p. Over the last year, Maxcyte shares have traded in a share price range of 172.50p to 430.00p.

Maxcyte currently has 103,504,571 shares in issue. The market capitalisation of Maxcyte is £433.68 million. Maxcyte has a price to earnings ratio (PE ratio) of -18.40.

Maxcyte Share Discussion Threads

Showing 626 to 650 of 1475 messages
Chat Pages: Latest  35  34  33  32  31  30  29  28  27  26  25  24  Older
DateSubjectAuthorDiscuss
16/4/2021
09:41
Thanks to Sahara for sending me this - very interesting (short podcast). What it underlines is maxcyte's importance in the gene editing space when it comes to the practical side of mass delivery (assuming we get there)...because the manufacturing of the allogeneic treatments is as important as the science of crispr itself in terms of the commercial reality of it all.
nimbo1
15/4/2021
22:29
Couple of chunky late reported trades worth £357k means things may be stirring...
cooltools
15/4/2021
15:14
Interesting to see that all the old corporate material (ending 2016) on the Nasdaq site has been removed in the past few hours.

We could hope it may be in preparation for a new listing!?!

EDIT - old documents have re-appeared.

pob69
15/4/2021
13:22
not surprising it is taking Time to digest the large move up imo...always happens
nimbo1
15/4/2021
12:44
There mustbe a bit of an overhang looking at today's trades, hopefully swallowed whole next week.
assagai
15/4/2021
06:33
Yes, I would be surprised if we don't get an update on NAS listing. With results seems an obvious opportunity.
Fingers xxxd

assagai
15/4/2021
06:19
Results on the 20th April - we know what they are give or take due to detailed trading update. Interesting for me will be what 'acceleration of growth' actually means if any hints given for the coming year. I assume we'll also get a timetable for US listing plans.
nimbo1
14/4/2021
12:16
Reference to Maxcyte in this article

"...Kohli says that a lot of the opportunities for licencing the CRISPR-Cas9 technologies are already priced into companies like CRISPR Therapeutics and MaxCyte. “There is probably still a lot of long-term upside to be gained by investing in the platforms, and I suspect that these types of companies will stay high return on invested capital companies rather than fading out as that time progresses. But just as exciting is the opportunity to invest in some of the companies that are looking to use the ‘genetic scissors’ to create new products.”"

pob69
14/4/2021
08:33
Could well be but last year 21st, a Tuesday. 2019 24th , a Wednesday.
assagai
14/4/2021
08:20
Assagai, Based on last year I thought Tuesday 20/4/2021.

CNBC saying,

Elsewhere, Wood said the genomics space is also set to hit escape velocity.

“DNA sequencing is going to introduce science into healthcare decision making for the first time,” said Wood. “We can honestly say that until now more than half of all healthcare decisions were in some part made through guesses or experiences. Now we’re going to have the data.”

ARK’s Genomics ETF has big bets on Exact Sciences, which makes up nearly 5% of the ETF, and Invitae. CRISPR Therapeutics is another major holding in the ETF.

“We’re going to be able to cure diseases that we never thought it would be possible to cure, including cancer,” said Wood.

bamboo2
14/4/2021
08:18
Results within 2 weeks?
Optimistic..

assagai
14/4/2021
08:06
Added a few more.

Spread just 1p at present, 844-845

Odd, just noticed I can buy at 844 and sell at 845!

bamboo2
14/4/2021
07:47
Last trade of 591 was a buy
montynj
07/4/2021
14:05
Bought back a few yesterday and today at 869 and 869.9
bamboo2
23/3/2021
18:56
Nice find by Sahara

'Interesting study by Glaxo comparing Maxcyte $MXCT to the distant #2 in electroporation Lonza

First time I've seen the difference quantified in a head-to-head comparison.'

homebrewruss
23/3/2021
09:08
That could be material to MXCT. Don't they get a revenue share from that?
donald pond
22/3/2021
17:07
MaxCyte, Inc. @MaxCyte_info

Congratulations to our partner, @SangamoTx, on the Orphan Designation for BIVV003 for the treatment of #sicklecelldisease: via @GENbio.

@sanofi @EMA_News #celltherapy #SCD

someuwin
15/3/2021
10:05
This is a 'picks and shovels' business to a high risk high reward industry, as such it benefits either way and doesn't carry the risk.

It also benefits if someone strikes gold, in that in addition, it earns royalties from successful outcomes.

One other positive is - it earns very high margin on equipment sales as well as the consumables. Usually, consumable businesses earn low margin on equipment sales and make their money on the consumable, this outfit is attractive.

owenski
15/3/2021
10:00
Valuation is impossible at the moment - could argue its worth billions or £7 a share depending on the view one wants to take or market conditions perhaps.

Some of the best investors in America wanted to got involved at £7 (this counts as the most recent independent valuation by professionals) and 2 brokers think it's worth £12 +. (But broker targets don't mean a lot to me other than perhaps potential direction of travel).

It'll be worth billions if a drug makes it to market and so far most advanced is Crispr Sickle Cell at 70% COS. But as ever nothing is certain until it happens.

One pays up, holds or sells accordingly. Under researched / unbalanced posting is just trolling and deserves to be ignored.

nimbo1
15/3/2021
07:58
Don't forget pre commercial milestones so it makes money as the drugs pass through clinical trials. Repeat sales of consumables and cell therapy drugs have already been approved it's not like this is a completely new area awaiting the first approval. Expecting more partnerships as well:-

As of February 2020, there are nine cell or gene therapy products approved in the U.S. – treating cancer, eye diseases and rare hereditary diseases. Biopharmaceutical researchers are using these new technologies and pursuing innovative treatments in clinical trials today.

"CELL AND GENE THERAPY - PhRMA Org". You can Google it to see the pdf document.

hj996
15/3/2021
07:48
The business model has parallels with that of ARM back in the mid-1990s. But of course the underlying therapeutics may not work in which case it is worth zero.
trickydicky1
14/3/2021
23:37
How much should the world leader in it chosen cell therapy field be worth? Not a leader but the leader. Why are US specialist funds rushing to buy up as much of the sells as they can? There were trades in the millions snapped up over £10. The question is not if they will struggle to sell but where will those companies in need of these products go? They will come knocking on MaxCyte's door. Why would they want to use an inferior competitors product when they are spending hundreds of millions on research and trials and MaxCyte's products will add extra value and efficiency to their drugs etc.? Only facts and solid opinions presented in the YouTube video.

It's actually a derisked way into the cell therapy field. Others take the risk and pay you for it as well. MaxCyte is therefore like a fund - stakes through the licensing, royalty agreements etc. in pretty much all the leading cell therapy companies and others. If one fails to succeed one or more of the others most likely will.

A unique business model where else will you find this? I recall the CEO saying as much in his latest talk that there is no other such business model.

hj996
14/3/2021
23:31
Zub

Everything is good for me at the right value and right price

stockready
14/3/2021
21:11
Thanks stockready. Sounds like its not for you this one, plenty more to chose from. GL
zubes
14/3/2021
20:41
Assagai

Thanks mate, yes managed to watch the youttube the right one this time
The CEO seems a camera shy Sarah had to tell him to turn on the camera.

It was an interesting presentation which he draw a very rosy pictures but fall short of explaining how many of these devices he is going to sell and how many he sold so far? These are the key questions people will ask
I don't care about how many sold in the past i care about hos projection to the future of how many he will sell!! Which none of that in the presentation

Also he mention Astra Zenica without mentioning the future relation andnif they need more, also lots of words such as ... likely, predicted, possible etc which is not really reassuring for the investors

If all the picture are so rosy why the share price is not £20 or evem more... surely some hesitation on the value and delivery what he says doesn't mean it will happen.
Pharma companies are so picky with their choice and need a book like thesis to convince them to buy anything. This is not as easy as he made it at all.

Overal nice solid idea but delivery to the market is far harder than portraited here

I am not saying is bad but i say be careful with how this is valued

GLA
IMHO

stockready
Chat Pages: Latest  35  34  33  32  31  30  29  28  27  26  25  24  Older

Your Recent History

Delayed Upgrade Clock